1. Burden of influenza B virus infection and considerations for clinical management.
- Author
-
Zaraket H, Hurt AC, Clinch B, Barr I, and Lee N
- Subjects
- Antiviral Agents therapeutic use, Child, Clinical Trials, Phase III as Topic, Dibenzothiepins pharmacology, Dibenzothiepins therapeutic use, Drug Resistance, Viral, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Humans, Influenza B virus drug effects, Influenza, Human drug therapy, Morpholines pharmacology, Morpholines therapeutic use, Pandemics prevention & control, Pyridones pharmacology, Pyridones therapeutic use, Triazines pharmacology, Triazines therapeutic use, Cost of Illness, Disease Management, Influenza B virus pathogenicity, Influenza, Human prevention & control
- Abstract
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. Finally, we offer considerations for the clinical management of influenza B, with a focus on children and high-risk patients where disease burden is highest., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF